ROTFLMAO
MarketByte LLC has been paid a fee of $100,000 in cash and 250,000 options convertible into free trading shares, exercisable at $3.50, by the Mohammed Patel, an individual, for publishing information on Diomed Corp for a period of one year. Please review our policy on selling shares found in our Mission Statement on our home page. MarketByte LLC has been paid a fee of $55,000 by Cove Hill Consultants for reporting on Dupont Direct Holdings.
listserv.otcjournal.com
Email : info@otcjournal.com
URL : otcjournal.com
To OTC Journal Members:
Diomed (Amex: DIO) On Good Morning America
Diomed, which is our current profile, traded to a high of $9 on Monday, but has since dropped back into the low $6 range. This week's pullback was initiated by a hatchet job article published about the company in Monday's NY Post which we covered in last Monday's edition.
The stock is rumored to have been targeted by a very powerful group of short sellers who are known for their aggressive smear campaigns. If this is true, we are anticipating more negative press on the company in high profile media. However, this press will not be focused on the company itself. The media will use rumor, innuendo, and names associated with the structuring of the deal to make the company look bad and try to scare investors into selling the stock to the benefit of short sellers.
Barron's might be a likely suspect for this type of yellow journalism. This weekly publication is well know in inner circles as a shill for short sellers, and some of their content is likened to the National Enquirer of the stock market by investment professionals. However, it should be noted that the bulk of the magazine is highly informative and has valuable information for investors.
They will not cover the business of the company itself. They will not mention some of the company's high profile investors which include Richard Branson via his personal money manager, Jack Rivkin of CitiGroup, billionaire financier Sam Belzberg, Bob Lessin of Witt Soundview, Matthew Bronfman of the Bronfman family, and high profile attorney Alan Dershowitz. These names are fully disclosed in the 8K filing with the SEC the company filed in conjunction with the reverse merger.
These and many others have put their own capital into the company. This does not guarantee the company will be successful, but it certainly lends credibility to the potential for Diomed's business model.
If the possibility of a short seller driven smear campaign frightens you, sell the stock and get out. Savvy investors will choose to wait it out, and will probably pounce on the stock in the event some article or news report with no substance drives the stock down artificially low levels. In the interim, we will continue reporting events and facts about the company, and remain convinced their business model has enormous upside potential.
If this sort of press does develop, we predict the stock will make its all time low just after the event. This will be a heaven sent opportunity for investors who are thinking of establishing their initial position, or those who wish to add to their existing holdings. Keep a clear head, study the facts, and remember how much money investors made who bought airline stocks on September 21, 2001 when the media had us believing the industry was about to go out of business.
The facts about Diomed can be obtained from documents filed with the SEC. If you are a serious investor you should read the company's February 14th 8K filing associated with their merger into a public shell. This is an enormous document and fully discloses everything you would want to know. You can access it through www.freeedgar.com, or click here and wait for it to open.
EVLT Featured on Good Morning America
Diomed's lasers and fiber are used in two separate FDA Approved therapies: PDT for cancer and EVLT for varicose veins. Investor interest in Diomed at this early stage is driven in large part by the market's perception of the enormous commercial potential for their EVLT therapy, a revolutionary new way to treat varicose veins.
In fact, interest is so high on EVLT that Good Morning America ran a special feature on this exciting new therapy one year ago when it was in clinical trials with the FDA. We have had many requests for the video of that feature, and we bring it to you today. It will play best on your computer through the Windows Media Player, so we have included a link to download this player if you do not have it installed.
Click Here to view if you have a High Speed Connection
Click Here if you have a Dial Up Connection
Click on the Icon to Download Windows Media Player
For those of you who access the Internet via dial up, please make every effort to get a broad band connection if you are serious about using the Internet. Your experience will be greatly enhanced.
More next week on Diomed if there are breaking events.
Dupont Direct Holdings (OTC BB: DIRX) Hits Milestone
We published a Trading Alert on Dupont Direct back on January 4th. The stock opened the following day at $1.39, much higher than our suggested $1 limit for a short term trade.
Dupont Direct is a boutique brokerage firm which specializes in managing fixed income portfolios for large institutions. They have developed highly creative strategies for enhancing bond yields, and the company is profitable and growing rapidly.
In the December quarter the company had earnings of $.03 per share fully diluted, which means they are at an annual run rate of $.12 per share in earnings.
Yesterday the company issued a press release indicating their growth continues at an unprecedented pace. The company hit the milestone of having $100 million under management, up from $65 million just two months ago.
One can reasonably expect earnings growth to accelerate from here. With the stock trading in the $.80 range, we still believe it could see the $2 mark if the investment community ever finds out about the company. Click Here to read yesterday's press release.
--------------------------------------------------------------------------------
Charts Provided Courtesy Of TradePortal.com
--------------------------------------------------------------------------------
The OTC Journal is a proud partner of the SwingWire.com Online Investment Community. A next generation Online Analyst Exchange providing Members the ability to search, review, track and monitor some of the Internet's best Online CAs (CyberAnalysts). Members have the opportunity to potentially achieve higher returns by viewing top performing portfolios and receiving real-time alerts from favorite CAs.
SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts!
Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today!
Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.
Click Here to view our compensation on every company we have ever covered, or visit the following web address: otcjournal.com for our full profiles and otcjournal.com for Trading Alerts.
MarketByte LLC has been paid a fee of $100,000 in cash and 250,000 options convertible into free trading shares, exercisable at $3.50, by the Mohammed Patel, an individual, for publishing information on Diomed Corp for a period of one year. Please review our policy on selling shares found in our Mission Statement on our home page. MarketByte LLC has been paid a fee of $55,000 by Cove Hill Consultants for reporting on Dupont Direct Holdings.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at sec.govand the National Association of Securities Dealers ("NASD") at nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at sec.gov. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. |
